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A b s t r a c t  
 
The main criteria for current vaccines design are effectiveness, efficaciousness and safety. 
Increasing requirements for vaccine safety and purity push forward not only classical vaccine devel-
opment, but also new generation vaccine technology, including sub-unit, recombinant, anti-
idiotypic, DNA vaccines etc. This recombinant technology has already demonstrated its advantage, 
efficaciousness and safety in a large field of therapeutic and curative drug development for animal 
and human (S. Khan et al., 2016). In 2011, six novel drugs were created based on the new Fc-fusion 
protein technology. Most of the newly developed drugs affect receptor-ligand interactions, acting as 
antagonists by blocking direct receptor binding, i.e. Enbrel (etanercept; Amgen, USA), Zaltrap 
(aflibercept; Sanofi, France), Arcalyst (rilonacept; Regeneron, USA), or as agonists for direct stim-
ulation of receptor function which augment immune response as Amevive (alefacept, Astellas, 
USA) does, or decrease immune response as Nplate (romiplostim; Amgen, USA) does. In this 
review, we pay attention to the most relevant results from the last few years for virus and bacterial 
vaccine designed based on Fc-fusion technology. The Fc-chimeras are hybrid sequences in which 
Fc-fragment of IgG (Fc-IgG) and targeted therapeutic protein are fused in an entire protein mole-
cule (V. Pechtner et al., 2017). In this fusion, the hinge region of Fc-IgG is a flexible spacer between 
therapeutic protein and conservative part of IgG. It helps to minimize potential negative effect of 
two functional domains to each other. Therapeutic drugs based on Fc-fusion proteins are divided in 
three types, the receptor-Fc, peptide-Fc, and monomer-Fc. The Fc-fused proteins have tremendous 
therapeutic potential, since Fc domain in this molecules helps to specifically augment the pharmaco-
dynamics values. Presence of Fc-domain in hybrid molecules prolongs half elimination of protein 
from plasma, which extends drug therapeutic activity and slows down kidney clearance for large 
molecules. Here, we summarize the most significant experimental data of Fc-fusion technology ap-
plication against such pathogens as human immunodeficiency virus (D. Capon et al., 1989), Ebola 
virus (K. Konduru et al., 2011), Dengue virus (M.Y. Kim et al., 2018), influenza virus (L. Du et al., 
2011), Mycobacterium tuberculosis (S. Soleimanpour et al., 2015), classical swine fever virus (Z. Liu 
et al., 2017). We also discuss the critical aspects of mechanism of action, drug design and Fc-fused 
protein production. Targeted activation of effector systems boosts protective potential of immuno-
genic molecules and broadens its application. The interest of this review is focused on an application 
of Fc-fused proteins as potential vaccines against infectious human and animal diseases. We also 
briefly discuss the perspectives of Fc-fused antigens for novel effective medicine developments using 
African swine fever virus as an example. 
 
Keywords: Fc fragment, human immunodeficiency virus, Ebola virus, influenza virus, tuber-
culosis, classical swine fever virus, African swine fever virus, vaccination 
 
Vaccination (immunization) is one of the most effective methods to 
manage infectious diseases of animals and humans. The number of developed 
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vaccines has increased significantly in recent years [1]. In 2017, the Pharmaceu-
tical Research and Manufacturers of America (PhRMA) has published a list of 
144 infectious disease vaccines under development [2]. The main requirements 
for modern vaccines are their efficiency, reliability, and absence of side effects 
[3]. Increasing requirements for vaccine safety and purity push forward not only 
classical vaccine development, but also new generation vaccine technologies, i.e. 
sub-unit vaccines, recombinant vaccines, anti-idiotypic vaccines, DNA vaccines, 
etc. New vaccines must also be targeted to successfully resist highly contagious 
infections that could not be treated before [4]. 
Emergent animal infections deserve special attention because of the need 
to prevent epidemics and restrict ability of pathogens to pass the interspecific 
barrier [5]. The creation of an effective vaccine against African swine fever virus 
(ASFV) remains one of the most acute and important problems over the past 
few years in domestic and world agriculture. Numerous studies are conducted by 
experts in many countries (Russia, USA, UK, Germany) to develop new and 
safe vaccines to cope with this virus [6]. 
The obtained results of the use of prototype vaccines against ASF virus 
demonstrate the protective effect of the homologous virus but do not provide 
protection against ASF viruses of heterologous origin. The problems are due to 
the biological characteristics of ASF virus and the lack of ability of antibodies to 
neutralize the virus [7]. Another distinctive feature of this virus is its extreme 
antigenic variability and heterogeneity. The data on the protective antigens of 
the virus and their role in the pathogenesis of the disease are also absent. The 
structure of the viral envelope, which includes a large number of glycated proteins, 
allows the virus to "mask" antigenic determinants and evade host’s immune sur-
veillance. One of the approaches to develop the means for treatment and preven-
tion of African swine fever was the study of the role of virus surface antigens 
(CD2v protein, C-lectin-like protein, P54 virus membrane protein) [6, 8]. 
The technology of recombinant proteins has proved its advantage, effec-
tiveness, and safety in a wide range of therapeutic and curative drugs against infec-
tious diseases of humans and animals [9]. In 2015, the U.S. Food and Drug Ad-
ministration (FDA) has approved more than 180 therapeutic fused proteins and 
peptides [10]. However, fused proteins have some disadvantages. Due to their 
small size and/or hydrolysis, these proteins are usually eliminated from the body 
rapidly. The short half-life of therapeutic proteins requires more frequent admin-
istration of the drug to maintain their effective concentration [11]. 
Two main strategies for improving the pharmacokinetics of the peptide 
or protein of interest exist. The first involves the formation of a repository or the 
introduction of an implant, which ensures the distribution of the drug from the 
site of introduction into the circulatory system using polymer and lipid micro-
particles [12]. The second is to reduce the rate of nephritic elimination of the 
target molecule by increasing its size [13]. It is achieved by increasing the hy-
drodynamic radius of the therapeutic protein by chemical conjugation with a 
large polymer such as polyethylene glycol (PEG) or by recombinant methods 
[14], as well as increasing the molecular weight of the protein to the threshold of 
passing through nephritic filtration (about 60-70 kDa) due to either non-
covalent fusion of the therapeutic peptide with a larger carrier protein, or cova-
lent fusion of the therapeutic peptide with the carrier protein using genetic re-
combination [15]. 
Quite often, an immunoglobulin fragment (IgG-Fc) is used as a fusion 
partner. A therapeutic protein fused with an IgG-Fc fragment may further pro-
vide a therapeutic effect that varies depending on the pathogenesis of the disease. 
Fc-fused proteins proved themselves well as therapeutic and prophylactic agents 
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[16]. In 2011, six drugs were created based on the Fc-fusion protein technology. 
Most of the Fc-fused proteins affect receptor-ligand interactions as antagonists 
either blocking direct receptor binding, i.e. Enbrel (etanercept; Amgen, USA), 
Zaltrap (aflibercept; Sanofi, France), Arcalyst (rilonacept; Regeneron, USA), 
or as agonists for direct stimulation of receptor function which augment immune 
response as Amevive (alefacept, Astellas, USA) does, or decrease immune re-
sponse as Nplate (romiplostim; Amgen, USA) does [17, 18]. The advantages of 
Fc-fusion drugs over other biopharmaceuticals are discussed in a number of pa-
pers [18-21]. The proteins obtained with this technology have greater therapeutic 
potential, as they are associated with the Fc-domain, which provides a targeted 
increase in the pharmacokinetics of the hybrid protein. It is proved that the 
presence of Fc-domain lengthens significantly the half-life of the proteins in the 
blood before their elimination, which prolongs therapeutic activity, and also 
leads to slower nephritic clearance for larger molecules [21]. 
This review has a particular emphasis on the most relevant recent find-
ings in the application of Fc-fusion technology to create vaccines against viral 
and bacterial agents, with special attention on the prospects of this method for 
the development of drugs to prevent ASF. 
The functions of the Fc-
fragment. Immunoglobulins G (IgG) are 
antibodies involved in the neutralization of 
bacterial and viral toxins, stimulation of 
phagocytosis, and complement fixation. IgG 
trigger the effector mechanism of the im-
mune response by interaction with the sur-
face of leukocytes via Fc-receptor (FcR) 
[22, 23]. This is the manifestation of anti-
body-dependent cell cytotoxicity which 
leads to the lysis of pathogen-infected cells 
by cytotoxic T-cells (cytotoxic T-cell, T-
killer, CD8+) [24]. About 85% of all se-
rum immunoglobulins (A, D, E, G, M types) are IgG (Fig. 1) [13]. As well as 
albumin, IgG has the longest half-life compared to other plasma proteins [25]. 
Due to the small molecular weight (about 150 kDa), IgG molecules diffuse 
freely from the vascular bed into the extracellular space where they perform a 
protective function. IgG can penetrate the placental barrier from the mother’s 
blood into the fetal blood [26]. 
Design and structure of Fc-fused proteins. IgG is a class of anti-
bodies that are most commonly used to treat infectious diseases. Various ligands, 
extracellular domains of the soluble receptor, viral antigen, etc. can act as the 
target peptide or protein [27]. Due to the increased size and natural IgG conver-
sion in the body, proteins fused to the Fc-fragment are protected from degrada-
tion because of their recycling which involves the neonatal FcRn receptor. 
Fc-chimeric sequences are hybrid molecules in which the Fc-fragment 
of IgG (Fc-IgG) and the target therapeutic protein are a single protein product 
derived from a gene construct. In this fusion, the FC-IgG hinge site is a flexible 
spacer between the therapeutic protein and the constant part of the immuno-
globulin, preventing the possible negative impact of the two functional domains 
on each other [15, 27]. 
The most common types of chimeric proteins are receptor-Fc, peptide-
Fc, and monomer-Fc (Fig. 2). 
One of the modern approaches in the creation of vaccines leading to the in-
Fig. 1. Structure of IgG antibody [10]. 
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duction of T-lymphocytes was implemented to produce a chimeric protein consist-
ing of an antigen and an adjuvant based on the IgG Fc-fragment [27, 28]. Such 
vaccines may be used as a subunit vaccine (purified protein) or as a vector carrying 
the gene of this chimeric protein [29]. 
The Fc-fusion technology 
has been successfully used to design 
vaccines against infectious diseases of 
humans and animals. 
Fc-fused proteins as 
antiviral vaccines. Fc-fused pro-
teins as vaccines against human im-
munodeficiency virus. The pioneer-
ing work by Capon et al. [30] on 
the use of Fc-fusion to develop 
remedies for acquired immunodefi-
ciency syndrome (AIDS) has re-
vealed the enormous potential of 
chimeric Fc-proteins for the treat-
ment of a wide range of diseases. 
Capon and colleagues showed that 
a hybrid protein based on the ex-
tracellular part of the CD4+ recep-
tor and Fc fragment of IgG, created for the treatment of HIV-1 (human immu-
nodeficiency virus 1) infection, prevents the virus entering cells. Antibodies to 
CD4+ blocked the penetration of HIV-1 virus into T-cells, and the human cells 
transfected with complementary DNA (cDNA) of CD4+ became insensitive to 
the infection. 
Soluble CD4+ (rCD4) receptor, devoid of transmembrane and cyto-
plasmic CD4+ sequences, can block the penetration of the HIV-1 virus into the 
cell, but this allows only temporary immunity to be formed [31, 32]. 
Fc-fused proteins as vaccines against the Ebola virus. The Ebola virus, be-
longing to the Filoviridae family, causes hemorrhagic fever in humans, which is 
characterized by high morbidity and mortality [33]. Filoviruses are classified as 
category A bioterrorism agents. The rVSV-ZEBOV vaccine is not commercially 
licensed but has been used under “extended access” conditions during Ebola 
outbreaks in North Kivu [34]. 
Currently, several types of recombinant vaccines based on different vec-
tors are being developed, including adenovirus, parainfluenza virus, Venezuelan 
encephalitis virus, vesicular stomatitis virus, virus-like particles carrying viral gly-
coprotein [35]. Glycoprotein (Gp) of filovirus is the main protective antigen due 
to which protection against infection is provided. 
In 2017, Konduru et al. [36] have reported the use of a chimeric protein 
of viral glycoprotein fused to the Fc-domain of immunoglobulin as a vaccine. 
The extracellular domain of the Zaire Ebola virus glycoprotein (ZEBOV) fused 
to the Fc-fragment of human immunoglobulin IgG1 (ZEBOVGP-Fc) was ex-
pressed in mammalian cells for this purpose. The results of the studies showed 
that the viral glycoprotein undergoes cleavage by furin [37]. Immunization of 
mice with the recombinant chimeric protein ZEBOVGP-Fc has activated T-cell 
immunity against ZEBOV virus and produced neutralizing antibodies against 
recombinant vesicular stomatitis virus (rVSV-GP). Mice vaccinated with the 
chimeric protein ZEBOVGP-Fc were protected from infection with a lethal dose 
of ZEBOV virus [38]. These results suggest that vaccination with only the chi-
meric protein ZEBOVGP-Fc may be sufficient to produce protective immunity 
 
Fig. 2. Protein-protein fusion of IgG Fc-fragment with 
target fragments: dimeric fusion with receptor pro-
teins (A, B; two versions of fusion with ligands), 
monomeric fusion with a target peptide (C),  dimeric 
fusion with a target peptide (D). 
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against the ZEBOV virus in mice. 
High protection against a virulent ZEBOV virus induced by the 
ZEBOVGP-Fc hybrid protein indicates that a subunit vaccine based on hybrid 
proteins (Filovirus GP-Fc) can protect against viral infection [39]. Filo-virus 
GP-Fc, containing a glycoprotein bound to the Fc-domain, can be used as a 
standalone vaccine or in combination with other drugs such as DNA vaccines, 
virus-like particles or viral vector vaccines that are currently being developed. 
Production of the subunit vaccine based on Filovirus GP-Fc hybrid proteins is 
commercially quite simple, and in the case of its application the impact of side 
effects reduces. However, to confirm the safety of the vaccine being developed 
based on filovirus GP-Fc hybrid proteins, additional experiments on Guinea pigs 
and monkeys are necessary [40]. 
Fc-fused proteins as vaccines against the influenza virus. Hemagglutinins 
(HAs) of human influenza viruses (H1 and H3 subtypes) and avian influenza 
virus (H5 subtype) were obtained as recombinant proteins fused with the Fc-
domain of a human immunoglobulin. Insect cells infected with baculovirus se-
creted recombinant HA-HuFc proteins (human influenza virus hemagglutinin 
fused with human Fc-domain of human immunoglobulin) as glycosylated oligo-
meric hemagglutinins. When mice were immunized with purified recombinant 
HA-HuFc protein in the absence of adjuvant, the obtained serum samples 
caused hemagglutination suppression, demonstrated epitope specificity and neu-
tralized the virus. Based on the obtained results, the authors concluded that hu-
man influenza virus hemagglutinins fused with the Fc-domain of immunoglobu-
lin can be candidate influenza vaccines [41-43]. 
Fc-fused proteins as vaccines against human papillomavirus. Human papil-
lomavirus (HPV) is a huge problem in modern health care. There are 15 types of 
genital HPV, causing about 5% of carcinomas, primarily cervical, anogenital, 
and oropharyngeal transmitted sexually. All types of HPV affecting human skin 
tend to cause a benign form of cancer [44]. Licensed HPV vaccines based on 
virus-like particles carrying the main capsid antigen L1 are effective against 
widespread types of virus, but do not protect against other types that cause skin 
lesions, and are not therapeutic. Vaccines with enhanced adjuvant properties, 
including small capsid antigen L2, which use capsid display and fusion with early 
HPV antigens or Toll-like receptor antagonists, are under development. 
According to Chen et al. [45], recombinant Fc-fused antigens of various 
viruses increase immunogenicity and induce synthesis of viral neutralizing anti-
bodies against HPV, provide protective immunity against virulent herpes virus 
type II, influenza, and Ebola viruses. Chen et al. [45] showed for the first time 
that the fusion of HPV epitope 16 L2 (positions 17-36 bp) with a recombinant 
ligand for the FcRs receptor can significantly increase the immunogenicity of the 
L2 peptide and induce the production of cross-neutralizing antibodies and pro-
tective immunity against a number of phylogenetically distant types of human 
papillomavirus. 
The modified Fc-fragment of human IgG1 can be used as a basis for the 
presentation of the L2 antigen to induce cross-neutralizing antibodies and pro-
tective immunity to different types of human papillomavirus. This type of re-
combinant fused protein is expressed in large quantities and can be easy purified. 
Therefore, the presentation of the L2 antigen together with the modified Fc-
fragment provides new opportunities for the development of a vaccine against 
human papillomavirus [46, 47]. 
Fc-fused proteins as vaccines against tuberculosis. Tuberculosis caused by 
Mycobacterium tuberculosis (Mtb) ranks second in morbidity and mortality 
among infectious diseases worldwide [48]. As per WHO estimates, about 1.6 mil-
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lion people died of tuberculosis in 2017, including 300,000 those HIV-infected 
[49]. An important feature of Mtb as a pathogen is its ability to survive for a 
long time inside the cell in a latent form that can later lead to an active tubercu-
lous. The TB vaccine (Bacille Calmette-Guérin, BCG) is the only available li-
censed TB vaccine. It provides a sufficiently high protection against pulmonary 
tuberculosis, from 60% to 80%, but does not protect against hidden infections 
[50]. Consequently, the necessity for a new, safe and effective TB vaccine and 
an innovative vaccination strategy that could prevent all forms of TB, especially 
latent TB is obvious. Most new TB vaccines are currently in different stages of 
clinical trials or preclinical studies [51]. 
Simultaneous vaccination with multiple Mtb antigens can improve the 
protective effect against various forms of tuberculosis. Multistage fused proteins 
have been developed using ESAT-6 as an acute-phase antigen, with HspX pro-
tein as a latent antigen, with mouse Fcp2a fragment. 
ESAT-6 antigen target is one of the most immunodominant and Mtb-
specific target antigens containing multiple immunogenic T-cell epitopes capable 
of enhancing the cellular immune response. Mtb ESAT-6 is an important candi-
date antigen for the TB vaccine. In mice, Guinea pigs, and primates, TB vaccine 
containing ESAT-6 provides a higher protection than BCG [52]. 
HspX is a 16 kDa protein also known as -crystallin Mtb that accumu-
lates in dormant mycobacteria predominantly. It is highly immunogenic and can 
cause a strong cellular immune response in patients exposed to Mtb. Secreted 
proteins, the Mtb10.4 (Rv0288), Mtb8.4 (Rv1174c), ESAT-6 (Rv3875) and 
Ag85B (Rv1886c) antigens, are also highly immunogenic and can provide strong 
protective immunity against infection with M. tuberculosis, which suggests that 
these are promising candidate antigens [53, 54]. 
Profiling of immunogens to Fc-receptors (FcRs), as well as antigen-
presenting cells (APCs) such as myeloid and plasmacytoid dendritic cells (DCs), 
monocytes, and macrophages can enhance the immune response in vitro and in 
vivo. This method is effective as it increases the half-life of the antigen and facil-
itates its uptake by APCs via FcRs and therefore increases cross-presentation 
efficiency for a powerful Th1 immune response. FcRI mediates selective uptake 
of antigens by dendritic cells, which leads to their delivery to the cytoplasm, 
where epitopes are recognized by the main class I histocompatibility complexes 
and presented to CD8+ cells. Cytotoxic T-lymphocytes (CTL) serve as an effec-
tive factor of cellular immunity for the destruction of intracellular pathogens. 
CTL activation via FcRs destroys an infected Mtb cell to form -interferon (IFN 
-), which activates infected macrophages to kill intracellular bacteria [55]. 
Fc-fused proteins as candidates to create a vaccine against Dengue fever. 
Dengue fever is an acute vector-borne viral disease that occurs with fever, intox-
ication, myalgia, arthralgia, rash, and lymphoid nodes enlargement. In some 
cases, Dengue fever develops the hemorrhagic syndrome, mainly in children un-
der 15 years [56]. Dengue fever occurs mainly in South and South-East Asia, 
Africa, Oceania, and the Caribbean. The annual incidence is about 50 million 
people [57]. The causative agent of Dengue fever belongs to arboviruses of the 
Flaviviridae family of the Flavivirus genus (arboviruses of antigenic group B) [58]. 
The licensed Dengvaxia® vaccine (Sanofi Pasteur, France) does not 
protect children under the age of 9; therefore, additional vaccination strategies 
are necessary to stop this growing global epidemic. To obtain humanized and 
highly immunogenic polymeric immunoglobulin G scaffold (PIGS) fused with 
domain III of Dengue virus glycoprotein E (D-PIGS), the plant cell expression 
system was used [59]. The immunogenicity of this IgG-Fc receptor-targeted 
candidate vaccine has been demonstrated in transgenic mice expressing human 
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FcRI/CD64 [60]. In addition, recombinant molecules stimulated antigen-
specific proliferation of CD4+ and CD8+ T-cells, as well as the production of 
neutralizing antibodies to IFN-. The purified D-PIGS fraction induced stronger 
immune activation than the monomeric form, indicating effective interaction 
with low-affinity Fc receptors on antigen-presenting cells. These results show 
that D-PIGS expressed in plants has the potential to be used as a single-
component vaccine against Dengue fever of serotype 2 [60, 61]. 
A new approach to vaccination against Dengue fever is based on the ap-
plication of Fc-fusion technology [62]. A design consisting of D-PIGS fused 
with Fc of mouse IgG2a showed high immunogenicity. To implement this ap-
proach, a version of the D-PIGS design using human immunoglobulin was cre-
ated to obtain a candidate vaccine against Dengue fever. D-PIGS has shown 
high immunogenicity in transgenic mice expressing the human IgG receptor 
and, more importantly, in human tonsil cell culture. Thus, D-PIGS induced 
memory cell responses, IFN- production, and neutralizing antibodies against all 
four Dengue virus serotypes. This Dengue vaccine, based on human domain III 
and IgG1 polymer scaffold, has a potential advantage over other vaccines. It is 
easy to manufacture and scale, the risk of infection with animal pathogens is 
minimal and, most importantly, no antigenic interference, usually associated 
with the use of a tetravalent vaccine, is observed. The latter advantage is provid-
ed by the use of the EDIII domain III sequences of surface glycoprotein fused 
with human IgG1-Fc [63]. 
Fc-fused proteins as a vaccine against classical swine fever virus (CSFV). 
In recent years, a combinatorial approach based on the baculovirus vector has 
been widely used to create candidate vaccines against CSF virus [64]. Screening 
of a number of vectors based on baculovirus revealed that the baculovirus vector 
expressing the Fc domain of swine IgG1 has the greatest antagonism to com-
plement (75.6%). Flow cytometry of transduced cells showed that in using this 
baculovirus vector the Fc-domain significantly increases the efficiency of trans-
duction and transgenic expression of the reporter genes [65]. 
The E2 protein of the CSF virus was fused with the Fc-domain of swine 
IgG1 and translation enhancers Syn21 and P10UTR were additionally linked to 
enhance antigen expression. The E2 protein of the CSF virus has been shown to 
be effectively expressed in both insect and mammalian cells. In pigs immunized 
with recombinant baculovirus, specific antibodies against the E2 protein respon-
sible for the neutralization of the CSF virus, activation of the cellular immune 
response, and secretion of IFN-were synthesized with high titers. These results 
indicate the potential for widespread use of the Fc-domain of swine IgG1 and 
the surface antigen of the CSF virus [66, 67]. 
 Thus, Fc-fusion technology has been successfully applied to the devel-
opment of ways to fight many infectious diseases of viral and bacterial etiology. 
Structural, capsid proteins, and surface glycoproteins act as protective antigens. 
Both purified recombinant proteins and viral vectors (baculoviruses, adenovirus-
es, etc.) can provide antigen delivery [66, 68]. Regardless of the antigen delivery 
method, Fc-fused molecules induce strong cellular and humoral immune re-
sponses. When using recombinant Fc-fusion protein in the baculovirus system as 
a candidate vaccine against classical swine fever virus, intramuscular, intraperi-
toneal or intranasal vaccination with such constructs has been shown to induce a 
persistent humoral and cellular immune response. High titers of CSF-specific 
and neutralizing antibodies, as well as increased secretion of IFN- indicate that 
baculovirus effectively delivers exogenous antigen to pig cells [65]. 
In other cases of Fc-technology application considered by the authors 
(Ebola, Dengue, human papillomavirus, tuberculosis causative agent), immun-
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ization of animals with purified recombinant proteins was used to create antigenic 
constructions and effective activation of cellular and humoral immunity was also 
noted. In this regard, the technology of Fc-fused viral antigens as an approach to 
the creation of candidate vaccines looks promising in the case of ASF virus, in 
particular when using the viral protein CD2v, responsible for serospecificity. 
So, the presented review demonstrates particular examples of the applica-
tion of the proteins Fc-fusion strategy for the development of candidate vaccines 
against dangerous animal and human infections. Targeted activation of effectors 
increases the protective potential of immunogenic molecules and expands the 
scope of their application. Fc-fusion technology of recombinant antigens is effec-
tive to create therapeutic drugs. This approach can be promising in the develop-
ment of candidate vaccines against African swine fever based on the CD2v antigen 
of the African swine fever virus. 
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